News Sentiment

CABA sentiment intelligence

Cabaletta Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.83 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-4.9% over one week, -0.4% over four weeks, trend active, and below fair value.

Latest direct headline Positive

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Rating of "Moderate Buy" by Analysts

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -4.9% Price reacting lower
Trend fit Trend active -0.4% over four weeks
Fair value -60.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 44
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 8
Stock Titan 8
simplywall.st 7
www.marketscreener.com 3
Insider Monkey 3
Quartr 2
Finviz 2

Event Lens

What the news is about

Classified themes
Market update 39
Earnings 11
Analyst action 5
Guidance 3
Balance sheet 2
Capital return 1
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
MarketBeat Direct company coverage

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Rating of "Moderate Buy" by Analysts

Cabaletta Bio, Inc. (NASDAQ:CABA) has received an average analyst rating of "Moderate Buy" from seven firms, with an average 1-year price target of $15.50. Recent analyst actions were mixed, including Guggenheim raising its target to $16 and Morgan Stanley cutting its target to $

Tone
Positive 63/100
Event
Analyst action
Published
22 Jul 2026 06:10
Source
MarketBeat
Quartr Direct company coverage

Cabaletta Bio (CABA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Cabaletta Bio (CABA) provided a summary of its Guggenheim Securities Emerging Outlook: Biotech Summit 2026 presentation, highlighting strategic program updates including pivotal myositis study enrollment, automated manufacturing for rese-cel, and upcoming Phase 1/2 data for autoi

Tone
Positive 74/100
Event
Guidance
Published
20 Jul 2026 01:12
Source
Quartr
TradingView Direct company coverage

ETFs Investing in Cabaletta Bio, Inc. Stocks

This article lists various ETFs that include Cabaletta Bio, Inc. (CABA) stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of CABA stock, issuer, management style, expense ratio, AUM, price, and performance metrics. The

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 10:10
Source
TradingView
24/7 Wall St. Direct company coverage

Cabaletta Bio : CABA

Cabaletta Bio Inc (CABA) is a biotech company focused on developing engineered T cell therapies for autoimmune diseases, particularly B cell-mediated conditions. Its lead project, DSG3-CAART, is in Phase I trials for mucosal pemphigus vulgaris, and the company is also exploring t

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:09
Source
24/7 Wall St.
TradingView Direct company coverage

Enterprise value to EBIT forward of Cabaletta Bio, Inc. – NASDAQ:CABA

The article provides financial information for Cabaletta Bio, Inc. (NASDAQ: CABA), specifically focusing on its enterprise value to EBIT forward. It indicates that the market was closed at the time of the data display and that there were no trades. The period value and change per

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 12:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Cabaletta Bio, Inc. – NASDAQ:CABA

The article focuses on the "Price to sales forward" metric for Cabaletta Bio, Inc. (NASDAQ: CABA). It appears to be a financial data snippet from TradingView, providing an overview of the company's financials for investors and analysts. However, no specific numerical data is pres

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 12:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of Cabaletta Bio, Inc. – NASDAQ:CABA

The article focuses on the "Price to book forward" financial metric for Cabaletta Bio, Inc. (NASDAQ: CABA). It presents a specific value for this metric and indicates whether it has changed. The content appears to be a snapshot from a financial data platform like TradingView.

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 11:39
Source
TradingView
www.marketscreener.com Direct company coverage

Certain Common Stock of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 4-JUL-2026.

Certain common stock of Cabaletta Bio, Inc. are subject to a lock-up agreement that ends on July 4, 2026. These shares will be under lockup for 61 days, starting from May 4, 2026. The lock-up agreement prevents executive officers and directors from selling or otherwise disposing

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 23:39
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Cabaletta Bio, Inc.(NasdaqGS:CABA) added to Russell Small Cap Comp Growth Benchmark

Cabaletta Bio, Inc. (NasdaqGS:CABA) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is part of several recent additions to Russell Indices, signaling increased visibility and potential liquidity for the biotechnology company. Cabaletta Bio is a clini

Tone
Positive 74/100
Event
Balance sheet
Published
29 Jun 2026 17:08
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Value Benchmark

Cabaletta Bio, Inc. (NasdaqGS: CABA) has been added to the Russell 2000 Value Benchmark. This integration follows similar inclusions in other Russell indices, highlighting the company's growing presence in the market. Cabaletta Bio is a clinical-stage biotechnology company focuse

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 15:09
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 3000E Growth Benchmark

Cabaletta Bio, Inc. (NasdaqGS: CABA) has been added to the Russell 3000E Growth Benchmark, according to an announcement published on June 29, 2026. This news follows other recent index inclusions, including the Russell 3000 Index and the S&P Biotechnology Select Industry Index. T

Tone
Positive 76/100
Event
Market update
Published
29 Jun 2026 08:25
Source
marketscreener.com
Finviz Direct company coverage

CABA - Cabaletta Bio Inc Volatility & Greeks

This article provides a detailed financial overview of Cabaletta Bio Inc (CABA), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, volatility metrics, insider and institutional ownership,

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 09:39
Source
Finviz
TradingView Direct company coverage

Cabaletta Bio, Inc. Actuals & Estimates (NASDAQ:CABA)

This article provides an overview of Cabaletta Bio, Inc. (NASDAQ: CABA) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts with maximum and minimum price estimates, upcoming earnings report dates, and recent financi

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:39
Source
TradingView
TradingKey Direct company coverage

Cabaletta Bio Inc (CABA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article from TradingKey provides an overview of Cabaletta Bio Inc's (CABA) dividend and stock split history. It indicates that CABA has not distributed any dividends over the past five years and has no recorded stock split events. The page also displays current stock informa

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 20:40
Source
TradingKey
TradingKey Direct company coverage

Cabaletta Bio Inc (CABA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Cabaletta Bio Inc (CABA), listing major individual shareholders and the proportion of shares they hold. It also breaks down shareholder types by category (e.g., Hedge Fund, Investment Advisor) and provides institutional shareholdi

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 19:40
Source
TradingKey
Insider Monkey Direct company coverage

How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup

Cabaletta Bio (NASDAQ:CABA) is making progress with its experimental cell therapy, rese-cel, for autoimmune diseases. The company expects to file for FDA approval in myositis by 2027 and will release more clinical data for pemphigus vulgaris and lupus studies in the second half o

Tone
Positive 71/100
Event
Guidance
Published
17 Jun 2026 15:22
Source
Insider Monkey
Intellectia AI Direct company coverage

CABA Technical Analysis & Stock Price Forecast

This article provides a technical analysis and stock price forecast for Cabaletta Bio Inc (CABA), indicating a "Neutral" overall technical sentiment based on a combination of moving averages and oscillators. It details momentum indicators like RSI and MACD, key support and resist

Tone
Neutral 50/100
Event
Guidance
Published
17 Jun 2026 07:39
Source
Intellectia AI
Finviz Direct company coverage

CABA - Cabaletta Bio Inc Stock Price and Quote

This article provides a detailed financial overview and recent news for Cabaletta Bio Inc. (CABA). It includes stock performance metrics, analyst ratings, insider transaction data, and a comprehensive list of press releases and announcements related to their clinical trials and f

Tone
Positive 70/100
Event
Analyst action
Published
13 Jun 2026 03:09
Source
Finviz
Stock Titan Direct company coverage

Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22

Cabaletta Bio (CABA) director Richard C. Henriques Jr. was granted stock options for 22,000 shares at an exercise price of $3.22 per share. These options expire on June 8, 2036, and will vest in full on the earlier of June 9, 2027, or the date of the company's next annual stockho

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 13:39
Source
Stock Titan
Stock Titan Direct company coverage

Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares

Cabaletta Bio stockholders approved an amendment to the company's charter to increase authorized common shares from 300,000,000 to 600,000,000 at their annual meeting on June 9, 2026. This change expands the company's capacity to issue new equity in the future. Additionally, stoc

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 11:09
Source
Stock Titan
Stock Titan Direct company coverage

Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options

Cabaletta Bio director Simon Mark received a grant of 22,000 stock options as part of his compensation package. These options have an exercise price of $3.22 per share, expire on June 8, 2036, and will vest in full by June 9, 2027, or the company's next annual stockholder meeting

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 23:08
Source
Stock Titan
Stock Titan Direct company coverage

22,000 options granted to Cabaletta Bio (CABA) director Brun

Cabaletta Bio (CABA) director Scott C. Brun was granted 22,000 stock options with an exercise price of $3.22 per share, expiring on June 8, 2036. These compensation-related options vest fully on the earlier of June 9, 2027, or the date of the next annual stockholder meeting. Foll

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 23:08
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Cabaletta Bio, Inc. Insider Trading Activity

Cabaletta Bio, Inc. director Shawn Tomasello was granted stock options for 22,000 shares with an exercise price of $3.22. This grant is a compensation-related award, not an open-market transaction, and vests fully by June 9, 2027, or the next annual meeting. Following this, Tomas

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 23:08
Source
Stock Titan
TradingView Direct company coverage

CABA: Rese-cel delivers durable, safe remissions in myositis, supporting rapid outpatient adoption

Cabaletta Bio's Rese-cel shows durable, immunomodulator-free remissions and strong safety in myositis patients, allowing for outpatient dosing and quick adoption. The company plans a BLA submission in the second half of 2027, potentially benefiting from a priority review voucher

Tone
Positive 92/100
Event
Market update
Published
08 Jun 2026 16:09
Source
TradingView